Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
PARIS and LONDON – July 31, 2020 – Sanofi and GSK announced a collaborative effort with the U.S. government. To boost the progression and manufacture of a COVID-19 recombinant protein vaccine.
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.
Collaborating with the U.S. Department of Health and Human Services (HHS) and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the United States for the recombinant protein-based, adjuvanted vaccine, resulting in a significant increase in capacity.
“The vaccine portfolio being prepared for Operation Warp Speed increases the chances of having at least one safe and effective vaccine until the end of this year,” HHS Secretary Alex Azar said. “Today’s investment supports clinical trials and the manufacture of Sanofi and GSK adjuvants, with the possibility of bringing millions of safe and effective doses to the American people.”
Sanofi leads the clinical progression and registration of the COVID-19 vaccine and hopes phase 1/2 will begin in September, followed by a Phase 3 until the end of 2020. If knowledge is positive, corporations can apply in the U.S. regulatory approval in the first part of 2021. At the same time, Sanofi and GSK are stepping up the manufacture of antigens and adjuvants to produce up to one billion year-consistent doses worldwide.
Attachment file